In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...

And based on the data so far, amycretin looks even more impressive than Wegovy and Eli Lilly's Zepbound, the two top-selling weight loss drugs. In a 72-week study, Zepbound's mean weight loss was ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

Zepbound. We recently compiled a list of the 12 Best Long Term Low Risk Stocks to Buy Right Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands ...

However, they may trigger minor to moderate weight loss as a result of appetite suppression. Even so, GLP-1 agonists like Wegovy, Zepbound, and Saxenda (made with the same active ingredient as Victoza ...

UN Women Regional Director for Asia and the Pacific, Christine Arab, concluded a four-day visit to Papua New Guinea (PNG), reaffirming the organization’s commitment to supporting the Government of PNG ...